Enforcement action will be taken against any company marketing the products for children under the age of 3 or who are at low or moderate risk for tooth decay.
US consumer health company Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for ...
Not long after President Trump made his statement, Kenvue and Johnson & Johnson got into another complicated legal mess when ...
This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key takeaways: You can get semaglutide injections (Ozempic® and Wegovy®) ...
Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...
Early data from the ADAPT JR trial suggest efgartigimod may benefit adolescents with generalized myasthenia gravis, a rare ...
KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...
News-Medical.Net on MSN
Inconsistent labels and risky doses found in turmeric supplements worldwide
A global analysis of 125 turmeric supplements across five major markets revealed widespread inconsistencies in labeling, ...
Imagine reaching for your daily medication, only to learn it could be putting your health at risk. That's the reality facing ...
Biden-era licenses permitting limited US oil operations in Venezuela were revoked by the Trump administration in March 2025, ...
MedPage Today on MSN
Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug
The FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare mitochondrial depletion syndrome, the agency announced on Monday. A pair of ...
The U.S. military’s campaign against drug cartels has killed 64 people and destroyed 16 boats. Here's when the strikes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results